The clinical behaviour of each appear similar to one another and possibly distinct from patients with NSCLC without driver mutations, [3, 15] most notably exhibiting similar objective response rates, (74% for ALK+ NSCLC [5] and 72% for ROS1+ NSCLC [7]). The gene discussed is ALK; the disease is non-small cell lung carcinoma.